Table 2.
Analysis of EBNA1 promoter usage in Epstein-Barr virus (EBV) associated disorders
| Sample type | Qp | Cp | Fp* | BARTs |
| In vitro systems | ||||
| JY cells23 | + | + | + | + |
| C15 tumours22 | + | – | + | + |
| In vivo disorders | ||||
| Infectious mononucleosis (n = 1) | 1/1 | 1/1 | 1/1 | 1/1 |
| Reactive node, EBV positive cells (n = 1) | 1/1 | 0/1 | ND | 1/1 |
| Nasopharyngeal carcinoma (n = 15) | 15/15 | 5/15 | 0/5 | 15/15 |
| Lymphomas in patients without overt immunodeficiency | ||||
| Hodgkin's disease (n = 19) | 14/19 | 4/19 | 0/13 | 19/19 |
| Burkitt's lymphoma (n = 4) | 3/4 | 0/2 | 1/2 | 4/4 |
| Anaplastic large cell lymphoma (n = 1) | 1/1 | 0/1 | 0/1 | 1/1 |
| Nasal T/NK cell lymphoma (n = 6) | 6/6 | 0/5 | 0/2 | 6/6 |
| B non-Hodgkin's lymphoma (n = 4) | 2/4 | 1/4 | ND | 4/4 |
| Nodal PTCL NOS (n = 3) | 2/3 | 1/3 | 0/2 | 3/3 |
| Lymphomas in immunocompromised patients | ||||
| AIDS related lymphoma (n = 2) | 2/2 | 1/2 | 0/2 | 2/2 |
| Post-transplant LPD (n = 7) | 6/7 | 7/7 | 3/6 | 7/7 |
*Some cases could not be tested owing to lack of material.
BARTs, BamH1-A region driven transcripts; EBNA1, EBV nuclear antigen 1; LPD, lymphoproliferative disease; ND, not done; NK, natural killer; PTCL NOS, peripheral T cell lymphomas not otherwise specified.